| Id |
Subject |
Object |
Predicate |
Lexical cue |
| TextSentencer_T1 |
0-52 |
Sentence |
denotes |
Lack of p16/CDKN2 alterations in thyroid carcinomas. |
| T1 |
0-52 |
Sentence |
denotes |
Lack of p16/CDKN2 alterations in thyroid carcinomas. |
| TextSentencer_T2 |
53-316 |
Sentence |
denotes |
Exons 1-3 of the p16/CDKN2 gene and exons 4-9 of the p53 gene were screened for mutations by single-strand conformation polymorphism (SSCP) analysis and direct sequencing of PCR-amplified DNA from human primary thyroid carcinomas and thyroid carcinoma cell lines. |
| T2 |
53-316 |
Sentence |
denotes |
Exons 1-3 of the p16/CDKN2 gene and exons 4-9 of the p53 gene were screened for mutations by single-strand conformation polymorphism (SSCP) analysis and direct sequencing of PCR-amplified DNA from human primary thyroid carcinomas and thyroid carcinoma cell lines. |
| TextSentencer_T3 |
317-510 |
Sentence |
denotes |
The samples included 21 papillary carcinomas, 2 undifferentiated carcinomas, 1 follicular carcinoma, 1 medullary carcinoma and 2 cell lines originating from thyroid undifferentiated carcinomas. |
| T3 |
317-510 |
Sentence |
denotes |
The samples included 21 papillary carcinomas, 2 undifferentiated carcinomas, 1 follicular carcinoma, 1 medullary carcinoma and 2 cell lines originating from thyroid undifferentiated carcinomas. |
| TextSentencer_T4 |
511-623 |
Sentence |
denotes |
No homozygous deletions and mutations in the p16/CDKN2 were observed in any of the primary tumors or cell lined. |
| T4 |
511-623 |
Sentence |
denotes |
No homozygous deletions and mutations in the p16/CDKN2 were observed in any of the primary tumors or cell lined. |
| TextSentencer_T5 |
624-744 |
Sentence |
denotes |
In contrast, one of the two undifferentiated carcinomas an both cell lines demonstrated point mutations in the p53 gene. |
| T5 |
624-744 |
Sentence |
denotes |
In contrast, one of the two undifferentiated carcinomas an both cell lines demonstrated point mutations in the p53 gene. |
| TextSentencer_T6 |
745-961 |
Sentence |
denotes |
These results that p16/CDKN2 gene alteration is not required for malignant transformation in the thyroid, while p53 gene mutations may play a role in the progression from differentiated to undifferentiated carcinoma. |
| T6 |
745-961 |
Sentence |
denotes |
These results that p16/CDKN2 gene alteration is not required for malignant transformation in the thyroid, while p53 gene mutations may play a role in the progression from differentiated to undifferentiated carcinoma. |